Indian Journal of Clinical and Experimental Ophthalmology
Official Publication of Innovative Education and Scientific Research Foundation
Official Publication of Innovative Education and Scientific Research Foundation
Print ISSN: 2395-1443
Online ISSN: 2395-1451
CODEN : IJCEKF
Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...Original Article
Author Details :
Volume : 2, Issue : 4, Year : 2016
Article Page : 391-394
Abstract
This retrospective comparative study describes the surgical outcomes of primary external DCR by two instrument sets Kerrisons punch vs Lacrimal trephine. We reviewed the medical records of total forty eight patients who had undergone primary external DCR in the last one year period in our institution. Procedure success rate was among Kerrisons group 91.66% vs 83.33% in lacrimal Trephine group(p=0.157),that was marginally significant. But the operative time was slightly higher in Kerrison punch group. Chances of nasal mucosal damage was higher in lacrimal Trephine group. The follow-up period was upto six months after surgery.
How to cite : Kumar S, Kumar P, Chandra B, To study the surgical outcomes of external dacryocystorhinostomy (Trephine Vs Punch): a comparative retrospective study. Indian J Clin Exp Ophthalmol 2016;2(4):391-394
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
